<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856804</url>
  </required_header>
  <id_info>
    <org_study_id>TRITAL</org_study_id>
    <nct_id>NCT00856804</nct_id>
  </id_info>
  <brief_title>Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance</brief_title>
  <acronym>TRITAL</acronym>
  <official_title>Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Seville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INDICATION:&#xD;
&#xD;
      Patients with chronic hepatitis C, genotype 1 and non-responders to standard treatment for&#xD;
      hepatitis C.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
        1. ascertain the rate of sustained response in patients with hepatitis C, genotype 1 with&#xD;
           peginterferon + ribavirin resistance.&#xD;
&#xD;
        2. To know the response rate in 12 weeks&#xD;
&#xD;
        3. Describe the tolerance and safety of thalidomide in combination with peginterferon and&#xD;
           ribavirin.&#xD;
&#xD;
      DESIGN OF TEST Pilot Study:&#xD;
&#xD;
      The single arm study will:&#xD;
&#xD;
      1. Thalidomide 200 mg and peg-interferon alfa 2b (based on weight: 50-120 mcg / week) +&#xD;
      ribavirin (based on weight: 1000-1200mg / day)&#xD;
&#xD;
      Be tracked for 24 weeks after treatment.&#xD;
&#xD;
      Suspended treatment of 12 weeks in patients who have failed a drop of HCV RNA&gt; 2 log.&#xD;
&#xD;
      Patients who have been suspended for any reason, the treatment will be followed during 24&#xD;
      weeks, to assess safety parameters.&#xD;
&#xD;
      SUBJECT NUMBER: 10&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological response at week 12</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained virological response 24 weeks after the end of therapy</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of using thalidomide together with SOC.</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thalidomide added to peg-interferon + ribavirina</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>thalidomide adding to peginterferon + ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women in non fertile age.&#xD;
&#xD;
          -  HCV RNA detectable in serum.&#xD;
&#xD;
          -  Chronic hepatitis C virus with non-cirrhotic compensated liver disease (clinical&#xD;
             classification according to Child-Pugh Grade A) (Appendix 1).&#xD;
&#xD;
          -  Genotype 1.&#xD;
&#xD;
          -  Not responding to treatment with peginterferon alfa-2a in combination with Ribavirin.&#xD;
&#xD;
          -  Effective contraceptive measures during treatment and for 6 months after treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the following will not be selected for treatment:&#xD;
&#xD;
          -  Patients with liver biopsy compatible with cirrhosis F4 Metav classification.&#xD;
&#xD;
          -  Patients diagnosed with diabetes or basal glycemia higher than 126 mg / dl&#xD;
&#xD;
          -  Women and men of childbearing age&#xD;
&#xD;
          -  Treatment with systemic antineoplastic or immunomodulatory (including&#xD;
             suprafisiológicas doses of steroids and radiotherapy) 6 months before the first dose&#xD;
             of treatment.&#xD;
&#xD;
          -  Treatment with any investigational drug 6 weeks before the first dose of treatment.&#xD;
&#xD;
          -  History or other evidence of any pathology associated with chronic liver disease than&#xD;
             HCV.&#xD;
&#xD;
          -  Signs or symptoms of hepatocellular carcinoma.&#xD;
&#xD;
          -  History or other evidence of bleeding due to esophageal varices or other conditions&#xD;
             consistent with decompensated liver disease.&#xD;
&#xD;
          -  neutrophil count &lt;1500 células/mm3 or platelet count &lt;90,000 células/mm3 at Screening.&#xD;
&#xD;
          -  Hb &lt;12 g / dL in women or &lt;13 g / dL in men, at the time of evaluation.&#xD;
&#xD;
          -  Patients with baseline increased risk of anemia (eg thalassemia, spherocytosis,&#xD;
             history of gastrointestinal bleeding, etc.). Or where the presence of anemia would be&#xD;
             a medical problem.&#xD;
&#xD;
          -  Patients with documented or presumed coronary artery disease or cerebrovascular&#xD;
             disease should not be treated if in the opinion of the investigator, could not&#xD;
             tolerate an adequately sharp decline in hemoglobin.&#xD;
&#xD;
          -  serum creatinine&gt; 1.5 times above the normal upper limit at the time of valuation.&#xD;
&#xD;
          -  History of severe psychiatric illness, particularly depression. Is defined as a&#xD;
             serious psychiatric illness requiring treatment with antidepressants or major&#xD;
             tranquilizers in therapeutic doses required for major depression or psychosis,&#xD;
             respectively, for at least 3 months at any time before or any of the following&#xD;
             background: attempted suicide, hospitalization due to of psychiatric illness, or&#xD;
             period of disability due to psychiatric illness.&#xD;
&#xD;
          -  History of seizure disorder or current use of major anticonvulsants.&#xD;
&#xD;
          -  History of immune disease, chronic lung disease associated with limited functionality,&#xD;
             serious heart disease, congestive heart failure, advanced atherosclerosis, increased&#xD;
             organ transplant or other signs of serious disease, neoplasia, or any other condition&#xD;
             deemed by the investigator, prevent the patient is suitable for the study.&#xD;
&#xD;
          -  A history of thyroid disease poorly controlled with medications prescribed, elevated&#xD;
             concentrations of thyroid stimulating hormone (TSH) with increased thyroid peroxidase&#xD;
             antibodies and any clinical manifestation of thyroid disease.&#xD;
&#xD;
          -  Pathology involving a risk of acute renal function: dehydration (diarrhea, vomiting),&#xD;
             fever, infectious states and / or hypotonic severe (shock, sepsis, urinary infection,&#xD;
             neuropathy).&#xD;
&#xD;
          -  Evidence of severe retinopathy (eg CMV retinitis, macular degeneration).&#xD;
&#xD;
          -  Exploration programanada radiation with intravenous administration of contrast media&#xD;
             (IVU, angiography).&#xD;
&#xD;
          -  Evidence of drug use in the year prior to study.&#xD;
&#xD;
          -  Consumption of alcohol.&#xD;
&#xD;
          -  Inability or unwillingness to give informed consent or to comply with the requirements&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Romero-Gomez, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valme University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel Romero-Gomez, M.D.Ph.D</last_name>
    <phone>+34 955 015761</phone>
    <email>mromerogomez@us.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Romero-Gomez, M.D. Ph.D</last_name>
      <phone>+34 955015761</phone>
      <email>mromerogomez@us.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 3, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Manuel Romero-Gomez</name_title>
    <organization>Valme University Hospital</organization>
  </responsible_party>
  <keyword>Thalidomide</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Interferon resistance</keyword>
  <keyword>Immunomodulators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

